The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy: A Randomized Controlled Trial
Open accessAbstract
CONTEXT: The Women's Health Initiative Estrogen-Alone Trial was stopped early after a mean of 7.1 years of follow-up because of an increased risk of stroke and little likelihood of altering the balance of risk to benefit by the planned trial termination date. Postintervention health outcomes have not been reported. OBJECTIVE: To examine health outcomes associated with randomization to treatment with conjugated equine estrogens (CEE) among women with prior hysterectomy after a mean of 10.7 years of follow-up through August 2009. DESIGN, SETTING, AND PARTICIPANTS: The intervention phase was a double-blind, placebo-controlled, randomized clinical trial of 0.625 mg/d of CEE compared with placebo in 10,739 US postmenopausal women aged 50 to 79 years with prior hysterectomy. Follow-up continued after the planned trial completion date among 7645 surviving participants (78%) who provided written consent. MAIN OUTCOME MEASURES: The primary outcomes were coronary heart disease (CHD) and invasive breast cancer. A global index of risks and benefits included these primary outcomes plus stroke, pulmonary embolism, colorectal cancer, hip fracture, and death. RESULTS: The postintervention risk (annualized rate) for CHD among women assigned to CEE was 0.64% compared with 0.67% in the placebo group (hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.75-1.25), 0.26% vs 0.34%, respectively, for breast cancer (HR, 0.75; 95% CI, 0.51-1.09), and 1.47% vs 1.48%, respectively, for total mortality (HR, 1.00; 95% CI, 0.84-1.18). The risk of stroke was no longer elevated during the postintervention follow-up period and was 0.36% among women receiving CEE compared with 0.41% in the placebo group (HR, 0.89; 95% CI, 0.64-1.24), the risk of deep vein thrombosis was lower at 0.17% vs 0.27%, respectively (HR, 0.63; 95% CI, 0.41-0.98), and the risk of hip fracture did not differ significantly and was 0.36% vs 0.28%, respectively (HR, 1.27; 95% CI, 0.88-1.82). Over the entire follow-up, lower breast cancer incidence in the CEE group persisted and was 0.27% compared with 0.35% in the placebo group (HR, 0.77; 95% CI, 0.62-0.95). Health outcomes were more favorable for younger compared with older women for CHD (P = .05 for interaction), total myocardial infarction (P = .007 for interaction), colorectal cancer (P = .04 for interaction), total mortality (P = .04 for interaction), and global index of chronic diseases (P = .009 for interaction). CONCLUSIONS: Among postmenopausal women with prior hysterectomy followed up for 10.7 years, CEE use for a median of 5.9 years was not associated with an increased or decreased risk of CHD, deep vein thrombosis, stroke, hip fracture, colorectal cancer, or total mortality. A decreased risk of breast cancer persisted. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00000611.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Design of the Women’s Health Initiative Clinical Trial and Observational Study
(1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,585
Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L., Gass, M., Lane, D., Rodabough, R. J., Gilligan, M. A., Cyr, M. G., Thomson, C. A., et al. (2003) · JAMA · doi:10.1001/jama.289.24.3243 · Cited by 1,872
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741
Self-citationThe use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487
Molecular and Cellular Basis of Cardiovascular Gender Differences
Mendelsohn, M. E., & Karas, R. H. (2005) · Science · doi:10.1126/science.1112062 · Cited by 1,101
Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk
Schairer, C. (2000) · JAMA · doi:10.1001/jama.283.4.485 · Cited by 1,048
Prentice, R. L., Caan, B., Chlebowski, R. T., Patterson, R., Kuller, L. H., Ockene, J. K., Margolis, K. L., Limacher, M. C., Manson, J. E., Parker, L. M., et al. (2006) · JAMA · doi:10.1001/jama.295.6.629 · Cited by 828
Self-citationHernán, M. A., Alonso, A., Logan, R., Grodstein, F., Michels, K. B., Willett, W. C., Manson, J. E., & Robins, J. M. (2008) · Epidemiology · doi:10.1097/ede.0b013e3181875e61 · Cited by 818
Estrogen Replacement Therapy and Fractures in Older Women
Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., Cummings, S. R., & and For The Study of Osteoporotic Fractures Research Group* (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00002 · Cited by 809
Estrogen Therapy and Coronary-Artery Calcification
Manson, J. E., Allison, M. A., Rossouw, J. E., Carr, J. J., Langer, R. D., Hsia, J., Kuller, L. H., Cochrane, B. B., Hunt, J. R., Ludlam, S. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071513 · Cited by 711
Outcomes ascertainment and adjudication methods in the women's health initiative
Curb, J. D., Mctiernan, A., Heckbert, S. R., Kooperberg, C., Stanford, J., Nevitt, M., Johnson, K. C., Proulx-Burns, L., Pastore, L., Criqui, M., et al. (2003) · Annals of Epidemiology · doi:10.1016/s1047-2797(03)00048-6 · Cited by 698
Stefanick, M. L., Anderson, G. L., Margolis, K. L., Hendrix, S. L., Rodabough, R. J., Paskett, E. D., Lane, D. S., Hubbell, F. A., Assaf, A. R., Sarto, G. E., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1647 · Cited by 571
Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women
Chlebowski, R. T., Anderson, G. L., Gass, M., Lane, D. S., Aragaki, A. K., Kuller, L. H., Manson, J. E., Stefanick, M. L., Ockene, J., Sarto, G. E., et al. (2010) · JAMA · doi:10.1001/jama.2010.1500 · Cited by 567
Grodstein, F., Manson, J. E., & Stampfer, M. J. (2006) · Journal of Women's Health · doi:10.1089/jwh.2006.15.35 · Cited by 479
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Chlebowski, R. T., Kuller, L. H., Prentice, R. L., Stefanick, M. L., Manson, J. E., Gass, M., Aragaki, A. K., Ockene, J. K., Lane, D. S., Sarto, G. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807684 · Cited by 472
Estrogen replacement therapy, atherosclerosis, and vascular function
Mikkola, T. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00466-7 · Cited by 420
Li, C. I. (2003) · JAMA · doi:10.1001/jama.289.24.3254 · Cited by 417
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin
Heiss, G. (2008) · JAMA · doi:10.1001/jama.299.9.1036 · Cited by 396
Understanding the Divergent Data on Postmenopausal Hormone Therapy
Grodstein, F., Clarkson, T. B., & Manson, J. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmsb022365 · Cited by 329
Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy
Beral, V., Reeves, G., Bull, D., Green, J., & Collaborators, F. T. M. W. S. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq527 · Cited by 292
Ellis, M. J., Gao, F., Dehdashti, F., Jeffe, D. B., Marcom, P. K., Carey, L. A., Dickler, M. N., Silverman, P., Fleming, G. F., Kommareddy, A., et al. (2009) · JAMA · doi:10.1001/jama.2009.1204 · Cited by 287
Unopposed Estrogen Therapy and the Risk of Invasive Breast Cancer
Chen, W. Y., Manson, J. E., Hankinson, S. E., Rosner, B., Holmes, M. D., Willett, W. C., & Colditz, G. A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.9.1027 · Cited by 251
Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy
Day, S., & Bevers, T. B. (2011) · Breast Diseases: A Year Book Quarterly · doi:10.1016/j.breastdis.2011.10.032 · Cited by 187
Estrogen Receptor Expression and Function in Long-Term Estrogen-Deprived Human Breast Cancer Cells1
Jeng, M.-H., Shupnik, M. A., Bender, T. P., Westin, E. H., Bandyopadhyay, D., Kumar, R., Masamura, S., & Santen, R. J. (1998) · Endocrinology · doi:10.1210/endo.139.10.6229 · Cited by 175
Fracture Incidence in Relation to the Pattern of Use of Hormone Therapy in Postmenopausal Women
Banks, E. (2004) · JAMA · doi:10.1001/jama.291.18.2212 · Cited by 167
Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000275404.76075.72 · Cited by 160
Self-citationFournier, A., Mesrine, S., Boutron‐Ruault, M., & Clavel‐Chapelon, F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6432 · Cited by 142
Prentice, R. L., Chlebowski, R. T., Stefanick, M. L., Manson, J. E., Langer, R. D., Pettinger, M. B., Hendrix, S. L., Hubbell, F. A., Kooperberg, C. L., Kuller, L. H., et al. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn090 · Cited by 135
Kerlikowske, K. M., Miglioretti, D. L., Ballard-Barbash, R. R., Weaver, D. L., Buist, D. S. M., Barlow, W. E., Cutter, G., Geller, B. M., Yankaskas, B. C., Taplin, S. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.151 · Cited by 129
Greendale, G. A., Espeland, M., Slone, S., Marcus, R., & Barrett-Connor, E. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.6.665 · Cited by 122
Dunbier, A. K., Anderson, H., Ghazoui, Z. F., Folkerd, E. J., A’Hern, R., Crowder, R. J., Hoog, J., Smith, I. E., Osin, P., Nerurkar, A. Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9616 · Cited by 120
Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L., Gass, M. L. S., Lane, D. S., Rodabough, R. J., Gilligan, M. A., Cyr, M. G., Thomson, C. A., et al. (2003) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000093674.44946.d6 · Cited by 119
Yates, J., Barrett-Connor, E. L., Barlas, S., Chen, Y.-T., Miller, P. D., & Siris, E. S. (2004) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000114986.14806.37 · Cited by 103
Santen, R. J., Song, R., Zhang, Z., et al. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.04.025 · Cited by 81
Adaptive Hypersensitivity to Estrogen
Santen, R. J., Song, R. X.-D., Zhang, Z., Yue, W., & Kumar, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-031207 · Cited by 75
Manson, J. E., & Bassuk, S. S. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm213 · Cited by 72
The use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C. H., ROSNER, B. A., & Speizer, F. E. (1995) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199511000-00017 · Cited by 70
Calle, E. E., Feigelson, H. S., Hildebrand, J. S., Teras, L. R., Thun, M. J., & Rodríguez, C. (2009) · Cancer · doi:10.1002/cncr.24101 · Cited by 64
McTiernan, A., Chlebowski, R. T., Martin, C. F., Peck, J. D., Aragaki, A. K., Pisano, E. D., Wang, C. Y., Johnson, K., Manson, J. E., Wallace, R. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7166 · Cited by 64
Prentice, R. L., Caan, B. J., Chlebowski, R. T., Patterson, R. E., Kuller, L. H., Ockene, J. K., Margolis, K. L., Limacher, M. C., Manson, J. E., Parker, L., et al. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000224658.90363.e7 · Cited by 40
Self-citation95007346 Estrogen replacement therapy and fractures in older women
Cauley, J. A., Seeley, D. G., Ensrud, K. E., Ettinger, B. B., Black, D., & Cummings, S. R. (1995) · Maturitas · doi:10.1016/0378-5122(95)99336-z · Cited by 34
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin
Dungan, J. S. (2009) · Yearbook of Obstetrics Gynecology and Women s Health · doi:10.1016/s1090-798x(09)79136-2 · Cited by 21
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Corson, S. L. (2009) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2009.02.003 · Cited by 20
Grodstein, F., Manson, J. E., & Stampfer, M. J. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000219473.28314.aa · Cited by 18
Chlebowski, R. T., & Anderson, G. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq561 · Cited by 17
Li, C. I., Malone, K. E., Porter, P. L., Weiss, N. S., Tang, M.-T. C., Cushing‐Haugen, K. L., & Daling, J. R. (2003) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000093673.42448.74 · Cited by 12
Brenner, R. J. (2010) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2010.10.049 · Cited by 4
Cited by
Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., et al. (2013) · JAMA · doi:10.1001/jama.2013.278040 · Cited by 1,650
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Sex/Gender Differences in Cardiovascular Disease Prevention: What a Difference a Decade Makes
Mosca, L., Barrett-Connor, E., & Kass Wenger, N. (2011) · Circulation · doi:10.1161/circulationaha.110.968792 · Cited by 1,045
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
The 2012 Hormone Therapy Position Statement of The North American Menopause Society
(2012) · Menopause · doi:10.1097/gme.0b013e31824b970a · Cited by 785
Metadata
- Authors
- LaCroix, A. Z.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-04-06
- Volume
- 305
- Issue
- 13
- Pages
- 1305
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2098663481
- Cited by
- 538
- References
- 51
- FWCI
- 64.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.